Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
28 hedge funds and large institutions have $7.9M invested in Vincerx Pharma, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 5 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
4% more funds holding
Funds holding: 27 → 28 (+1)
9% less capital invested
Capital invested by funds: $8.67M → $7.9M (-$773K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$491K |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$43.9K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$21.9K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$17.2K |
| 5 |
Jane Street
New York
|
+$14.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$193K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$144K |
| 3 |
Renaissance Technologies
New York
|
-$44K |
| 4 |
Millennium Management
New York
|
-$9.27K |
| 5 |
LPL Financial
San Diego,
California
|
-$8.32K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $151 | – | – | – |
|
27
JP Morgan Chase
New York
| $42 | +$41 | +3 | New |
|
|
FFA
28
Farther Finance Advisors
San Francisco,
California
| $7 | +$14 | +1 | New |
|
|
29
Citadel Advisors
Miami,
Florida
| – | -$144K | -8,912 | Closed |
|
|
30
Millennium Management
New York
| – | -$9.27K | -572 | Closed |
|
31
Focus Partners Wealth
Boston,
Massachusetts
| – | -$8K | -545 | Closed |
|
|
32
LPL Financial
San Diego,
California
| – | -$8.32K | -514 | Closed |
|
|
LP
33
LMR Partners
London,
United Kingdom
| – | -$8.1K | -500 | Closed |
|
34
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$4 | – | – |
|
VINC Hedge Fund Activity: Q3 2024 in Review
28 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q3 2024, worth a combined $7.9M — down 8.9% from $8.67M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new VINC positions and 5 closed out — a net gain of 1 holder — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Armistice Capital, adding an estimated $491K. The largest seller was Prosight Management, cutting an estimated $193K.
- 28 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q3 2024, up from 27 in Q2 2024.
- Funds reported $7.9M of Vincerx Pharma, Inc. Common Stock stock for Q3 2024, down 8.9% quarter-over-quarter.
- 6 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q3 2024 and 5 closed out, a net change of +1 holder.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q3 2024 was Armistice Capital, an estimated $491K added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q3 2024 was Prosight Management, an estimated $193K sold.
Based on aggregated 13F filings for Q3 2024.